# G. Michael Felker

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/g-michael-felker/

## Facts

| Field | Value |
| --- | --- |
| Citations | 48,158 |
| Field | Heart Failure Treatment and Management |
| h-index | 105 |
| i10-index | 384 |
| Last Known Institution | Duke University |
| OpenAlex ID | https://openalex.org/A5022076272 |
| ORCID iD | 0000-0002-5931-1239 |
| Works | 765 |

## Researcher papers

Showing 12 of 23.

- [Underlying Causes and Long-Term Survival in Patients with Initially Unexplained Cardiomyopathy](https://scholariq.org/papers/underlying-causes-and-long-term-survival-in-patients-with-initially-unexplained/)
- [Diuretic Strategies in Patients with Acute Decompensated Heart Failure](https://scholariq.org/papers/diuretic-strategies-in-patients-with-acute-decompensated-heart-failure/)
- [Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure](https://scholariq.org/papers/universal-definition-and-classification-of-heart-failure-a-report-of-the-heart/)
- [Effect of Nesiritide in Patients with Acute Decompensated Heart Failure](https://scholariq.org/papers/effect-of-nesiritide-in-patients-with-acute-decompensated-heart-failure/)
- [Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction](https://scholariq.org/papers/effect-of-phosphodiesterase-5-inhibition-on-exercise-capacity-and-clinical/)
- [Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome](https://scholariq.org/papers/ultrafiltration-in-decompensated-heart-failure-with-cardiorenal-syndrome/)
- [Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure](https://scholariq.org/papers/red-cell-distribution-width-as-a-novel-prognostic-marker-in-heart-failure/)
- [Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial](https://scholariq.org/papers/serelaxin-recombinant-human-relaxin-2-for-treatment-of-acute-heart-failure-relax/)
- [Decision Making in Advanced Heart Failure](https://scholariq.org/papers/decision-making-in-advanced-heart-failure/)
- [A standardized definition of ischemic cardiomyopathy for use in clinical research](https://scholariq.org/papers/a-standardized-definition-of-ischemic-cardiomyopathy-for-use-in-clinical/)
- [Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction](https://scholariq.org/papers/effects-of-liraglutide-on-clinical-stability-among-patients-with-advanced-heart/)
- [Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure](https://scholariq.org/papers/cardiac-myosin-activation-with-omecamtiv-mecarbil-in-systolic-heart-failure/)

## Researcher topics

- [Heart Failure Treatment and Management](https://scholariq.org/topics/heart-failure-treatment-and-management/)
- [Cardiovascular Function and Risk Factors](https://scholariq.org/topics/cardiovascular-function-and-risk-factors/)
- [Cardiac pacing and defibrillation studies](https://scholariq.org/topics/cardiac-pacing-and-defibrillation-studies/)
- [Mechanical Circulatory Support Devices](https://scholariq.org/topics/mechanical-circulatory-support-devices/)
- [Cardiac Fibrosis and Remodeling](https://scholariq.org/topics/cardiac-fibrosis-and-remodeling/)

## Researcher university

- [Duke University](https://scholariq.org/institutions/duke-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.